<DOC>
	<DOCNO>NCT01992484</DOCNO>
	<brief_summary>The aim study : - explore whether platelet reactivity patient treat wih novel platelet inhibitor associate clinical outcome - investigate whether therapeutic window exist novel platelet inhibitor - investigate incidence adverse event treatment novel platelet inhibitor real life clinical scenario - investigate association genetic polymorphism , inflammation , platelet reactivity clinical outcome - investigate synergistic effect aspirin novel platelet inhibitor</brief_summary>
	<brief_title>Platelet Function Patients With Acute Coronary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>Signed informed consent Acute coronary syndrome admission Planned treatment novel platelet inhibitor Age &gt; 18 * Participation interventional trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>platelet , Acute coronary Syndrome ( ACS ) , prasugrel , ticagrelor , aspirin</keyword>
</DOC>